INNOVATION 2013 WEEK

Welcome to UNeMed's inaugural

UNMC Startup Company Demonstration Day

Program:

Opening Remarks 2:30 p.m. Michael Dixon President & CEO, UNeMed Corporation Shane Farritor 2:35 p.m. Co-Founder, Virtual Incision Corporation About: Founded in 2006, Virtual Incision Corp. is a start-up company developing miniature robotic VIRTUALINCISION devices that are placed inside the body during laparoscopic surgery. VI surgical robots are introduced through laparoscopic ports using 4:15 p.m. a special insertion device. Once inside, the robots are controlled by the surgeon and enable complex procedures to be performed with minimally invasive techniques. Greg Gordon 2:55 p.m. Founder, Radux Devices About: Radux Devices, LLC, was created in 2012 to develop two RADUX UNMC inventions that improve radiation protection and decrease orthopedic stress for physicians. The devices also improve workflow and operating table management 4:35 p.m. in endovascular/fluoroscopy suites. Anna Brynskikh Boyum & Tom Frederick 3:15 p.m. Co-Founders, Elegant Instruments About: Elegant Instruments, LLC, is a development company that nstruments creates and commercializes innovative biomedical technologies to advance healthcare and biomedical research. It's mission is to make life better through the simple and effective solutions it provides. Two University of Nebraska students, Anna Brynskikh Boyum and Tom Frederick, founded the Omaha-based startup. 4:55 p.m. Sam Sanderson 3:35 p.m. Founder, Prommune About: Prommune Inc. is an early stage biotechnology company focused on the human and veterinary PROMMUNE

> therapeutic strategy for fighting infections by awakening the body's own natural immune defenses. Host-directed immunotherapy, or HDI, is induced by a structurally engineered peptide known as EP67. Prommune's EP67 selectively engages and activates the cell population responsible for innate immunity — the body's first line of defense against bacterial, viral and fungal infections.

INNOVATION IN IMMUNOTHERAPY

medicine applications of a novel

3:55 p.m.

Gary Madsen CEO, ProTransit Nanotherapy

About: ProTransit Nanotherapy, LLC, is a seed stage company focused on delivering medication with unique nanoparticles that are nontoxic and biodegradable. The



nanoparticles stabilize the drug, have a slow-release profile and can penetrate cell membranes to deliver powerful medications where they can be most effective. The first of several applications of this technology will be delivering antioxidant enzymes in sunscreens and cosmetics to deep layers of skin where it can help prevent premature wrinkles, age spots and even cancer.

Luis López Co-founder, Cardiosys

About: CardioSys combines advanced mathematical modeling and predictive analytics with data visualization in order to provide helpful insights into the health of individuals. Using fluid algorithms, the platform allows health insurers, third-party administrators, and brokers to forecast preventable life even



kers to forecast preventable life events and mitigate risk.

Ryan Mikluscak CEO, Motometrix

About: Motometrix is an early stage company formed around technology developed by a biomechanics researcher at the University of Ne-



braska at Omaha. The technology uses high level mathematics to measure nearly imperceptible changes in a person's posture and accurately diagnose the early onset of several brain disorders well before a patient presents symptoms. One application of the technology could be used on football sidelines to detect concussions within minutes after a violent collision.

Bruce Lichorowic CEO, Trak Surgical

About: Trak Surgical, Inc., is a surgical tool company built around an innovative software and bone saw package that could change the



way joint replacement surgeries are performed. The device is a next generation handheld surgical tool that uses software and a guidance system that may completely eliminate the need for expensive jigs and the specialized staff needed for current orthope-

5:15 p.m. Reception DRC Atrium

Complimentary snacks and refreshments provided



Monday, Oct. 7, 2:30-6:30 p.m. University of Nebraska Medical Center Durham Research Center I, Auditorium Omaha, Nebraska

